Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pulmonary arterial hypertension registries: past, present and into the future

Jason Weatherald, Abílio Reis, Olivier Sitbon, Marc Humbert
European Respiratory Review 2019 28: 190128; DOI: 10.1183/16000617.0128-2019
Jason Weatherald
1Dept of Medicine, Division of Respiratory Medicine, University of Calgary, Calgary, AB, Canada
2Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason Weatherald
  • For correspondence: jcweathe@ucalgary.ca
Abílio Reis
3Pulmonary Vascular Disease Unit, Medicine Dept, Centro Hospitalar Universitário do Porto, Hospital de Santo António, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Abílio Reis
Olivier Sitbon
4Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
5Service de Pneumologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
6INSERM UMR S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Sitbon
Marc Humbert
4Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
5Service de Pneumologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
6INSERM UMR S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Humbert
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Registries have greatly contributed to knowledge about PAH epidemiology, risk factors, prognosis and treatment. Future registries face unique challenges but may benefit from integration of multiple data sources and capitalising on “Big Data” opportunities. http://bit.ly/2OBpapG

Disease registries are important sources of real-world evidence that inform clinical practice and health policy, particularly when randomised controlled trials do not exist [1]. Much of what we know today about pulmonary arterial hypertension (PAH) has come from observational studies from national and/or international disease registries.

In this issue of the European Respiratory Review, Swinnen et al. [2] provide a concise and comprehensive overview of how various registries have contributed to the current and evolving state of knowledge on PAH. They illustrate some of the major successes of modern PAH registries, which have broadened our understanding of changing patient demographics, epidemiology, natural history, risk factors and prognosis in PAH. Despite their inherent limitations, registry data continue to influence clinical practice and treatment guidelines. For example, the most recent PAH treatment algorithm in the 2018 World Symposium on Pulmonary Hypertension [3] proposes a risk-based approach to therapy, based largely on independent validation of risk assessment strategies from European and US PAH registries [4–8]. Another example of the influence of registry data on clinical care is the common use of initial triple combination therapy with an intravenous prostacyclin, an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor for patients with high risk PAH, which comes from registry studies showing improved outcomes in treated patients [9], despite an absence of randomised controlled study data to support this practice.

Importantly, Swinnen et al. [2] highlight the differences between current and past PAH registries, and the methodological limitations inherent to registry-based study designs. However, there are many remaining questions about PAH that can likely only be addressed in the setting of large patient registries. The authors provide insightful perspective on future opportunities for PAH registries in the present era of “Big Data”. For rare diseases like PAH, there is enormous potential for future registries in terms of larger numbers of well-characterised patients across the globe with linkage to other data sources, such as health administrative data or biobanks. Such large scale, multinational initiatives could help us better understand aspects of PAH such as health resource utilisation in the real-world, geographic or sociocultural gaps in diagnosis or treatment, or the link between pharmacogenomic differences in populations and long-term outcomes. Other opportunities include the potential to integrate validated patient-reported data from mobile devices and digital health data or physical activity tracking apps with PAH registries. The authors also correctly note that future registries would be more useful if they use common data elements to permit sharing between countries and organisations, fostering collaboration and multinational research. The European Respiratory Society has supported several lung disease registries including the PHAROS (severe Pulmonary Hypertension mAnagement acROSs europe) Clinical Research Collaboration, which was launched in February 2019 (www.ersnet.org/research/clinical-research-collaborations). PHAROS will establish a platform for clinical research in pulmonary hypertension, in close collaboration with the European Reference Network (ERN)-LUNG [10]. During the selection process of the healthcare providers participating in the ERN-LUNG, essential information about the clinical and scientific expertise and infrastructure across Europe has been gathered. As part of the ERN-LUNG objectives, an inventory of existing national and local pulmonary hypertension registries has also been performed and interoperability to exchange data is under further evaluation. Coordination of existing and future European pulmonary hypertension registries is one of the key specific aims of PHAROS.

However, with large-scale international registry initiatives, database linkage, integration of patient-level digital mobile technology and data sharing come serious and legitimate concerns about data ownership and privacy. Data is now a valuable commodity, equally so for health data. Big Data offers great power, and with great power comes great responsibility. Recent global events, such as the Cambridge Analytica scandal, mobile data breaches and patient concerns over data security may further tighten regulations on sharing medical information to such an extent that future multinational registry initiatives are constrained to the point of being unfeasible. As clinicians and researchers participating in PAH registries, we have the dual responsibilities of advancing knowledge with the aim of improving care and outcomes, whilst ensuring patient privacy and confidentiality of data. The latter may be a major challenge, but one worth our efforts given the enormous potential of integrating new technologies and data sources into future PAH registries.

Footnotes

  • Provenance: Commissioned article, peer reviewed.

  • Conflict of interest: J. Weatherald reports grants, personal fees and non-financial support from Janssen Inc. and Actelion, personal fees and non-financial support from Bayer, personal fees from Novartis, and grants from Alberta Lung Association, Canadian Vascular Network, European Respiratory Society and Canadian Thoracic Society, outside the submitted work.

  • Conflict of interest: A. Reis reports grants, personal fees and non-financial support from Janssen Inc. and Actelion, outside the submitted work.

  • Conflict of interest: O. Sitbon reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, Bayer and Merck, grants from GlaxoSmithKline, grants, and personal fees from United Therapeutics and Gossamer Bio, outside the submitted work.

  • Conflict of interest: M. Humbert reports personal fees from Actelion and Merck, and grants and personal fees from Bayer, GSK and United Therapeutics, outside the submitted work.

  • Received September 26, 2019.
  • Accepted October 3, 2019.
  • Copyright ©ERS 2019.
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    U.S. Food & Drug Administration. Real-World Evidence. www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence Date last updated: 05 September 2019. Date last accessed: 17 September 2019.
  2. ↵
    1. Swinnen K,
    2. Quarck R,
    3. Godinas L, et al.
    Learning from registries in pulmonary arterial hypertension: pitfalls and Recommendations. Eur Respir Rev 2019; 28: 190050.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Galiè N,
    2. Channick RN,
    3. Frantz RP, et al.
    Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801889. doi:10.1183/13993003.01889-2018
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Hoeper MM,
    2. Kramer T,
    3. Pan Z, et al.
    Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50: 1700740. doi:10.1183/13993003.00740-2017
    OpenUrlAbstract/FREE Full Text
    1. Boucly A,
    2. Weatherald J,
    3. Savale L, et al.
    Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1700889. doi:10.1183/13993003.00889-2017
    OpenUrlAbstract/FREE Full Text
    1. Kylhammar D,
    2. Kjellström B,
    3. Hjalmarsson C, et al.
    A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018; 39: 4175–4181. doi:10.1093/eurheartj/ehx257
    OpenUrl
    1. Weatherald J,
    2. Boucly A,
    3. Launay D, et al.
    Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. Eur Respir J 2018; 52: 1800678. doi:10.1183/13993003.00678-2018
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Benza RL,
    2. Gomberg-Maitland M,
    3. Miller DP, et al.
    The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141: 354–362. doi:10.1378/chest.11-0676
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sitbon O,
    2. Jaïs X,
    3. Savale L, et al.
    Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691–1697. doi:10.1183/09031936.00116313
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Humbert M,
    2. Wagner TO
    . Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference Networks. Eur Respir J 2017; 49: 1700085. doi:10.1183/13993003.00085-2017
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 28 Issue 154 Table of Contents
European Respiratory Review: 28 (154)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary arterial hypertension registries: past, present and into the future
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pulmonary arterial hypertension registries: past, present and into the future
Jason Weatherald, Abílio Reis, Olivier Sitbon, Marc Humbert
European Respiratory Review Dec 2019, 28 (154) 190128; DOI: 10.1183/16000617.0128-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary arterial hypertension registries: past, present and into the future
Jason Weatherald, Abílio Reis, Olivier Sitbon, Marc Humbert
European Respiratory Review Dec 2019, 28 (154) 190128; DOI: 10.1183/16000617.0128-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Clinical and prognostic value of ventilatory efficiency in cardiorespiratory disorders
  • Guidance production before evidence generation for critical issues: COVID-19
  • Modulator treatment for people with cystic fibrosis
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society